153 related articles for article (PubMed ID: 11181547)
1. Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors.
Wei S; Teitelbaum SL; Wang MW; Ross FP
Endocrinology; 2001 Mar; 142(3):1290-5. PubMed ID: 11181547
[TBL] [Abstract][Full Text] [Related]
2. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
3. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
[TBL] [Abstract][Full Text] [Related]
4. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
Merle B; Itzstein C; Delmas PD; Chenu C
J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
[TBL] [Abstract][Full Text] [Related]
5. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
Sugatani T; Alvarez UM; Hruska KA
J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
[TBL] [Abstract][Full Text] [Related]
6. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC; Takada Y; Aggarwal BB
J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
[TBL] [Abstract][Full Text] [Related]
7. TNF-alpha expression is transcriptionally regulated by RANK ligand.
Zou W; Amcheslavsky A; Takeshita S; Drissi H; Bar-Shavit Z
J Cell Physiol; 2005 Feb; 202(2):371-8. PubMed ID: 15389596
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.
Lam J; Takeshita S; Barker JE; Kanagawa O; Ross FP; Teitelbaum SL
J Clin Invest; 2000 Dec; 106(12):1481-8. PubMed ID: 11120755
[TBL] [Abstract][Full Text] [Related]
9. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.
Zhang YH; Heulsmann A; Tondravi MM; Mukherjee A; Abu-Amer Y
J Biol Chem; 2001 Jan; 276(1):563-8. PubMed ID: 11032840
[TBL] [Abstract][Full Text] [Related]
11. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
12. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
13. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
15. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
Chaisson ML; Branstetter DG; Derry JM; Armstrong AP; Tometsko ME; Takeda K; Akira S; Dougall WC
J Biol Chem; 2004 Dec; 279(52):54841-8. PubMed ID: 15485831
[TBL] [Abstract][Full Text] [Related]
16. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
17. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Lacey DL; Tan HL; Lu J; Kaufman S; Van G; Qiu W; Rattan A; Scully S; Fletcher F; Juan T; Kelley M; Burgess TL; Boyle WJ; Polverino AJ
Am J Pathol; 2000 Aug; 157(2):435-48. PubMed ID: 10934148
[TBL] [Abstract][Full Text] [Related]
19. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.
Abu-Amer Y
J Clin Invest; 2001 Jun; 107(11):1375-85. PubMed ID: 11390419
[TBL] [Abstract][Full Text] [Related]
20. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
Wattel A; Kamel S; Prouillet C; Petit JP; Lorget F; Offord E; Brazier M
J Cell Biochem; 2004 May; 92(2):285-95. PubMed ID: 15108355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
